Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1169MR)

This product GTTS-WQ1169MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1169MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4525MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ12953MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ10897MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ6988MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ10471MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ1466MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ9004MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ2051MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW